Xinkeshu for coronary heart disease complicated with anxiety or depression: A meta-analysis of randomized controlled
Qian Liu1, Mengxi Wang2, Haiyan Wang2
1Emergency Department, Xi'an Hospital of Traditional Chinese Medicine, Xi'an, China.
Insights
Xinkeshu (XKS) combined with Western medicine significantly improves anxiety and depression in coronary heart disease (CHD) patients. This traditional Chinese medicine shows potential for safe and effective treatment, though more high-quality trials are needed.
Area of Science:
- Pharmacology
- Cardiology
- Psychiatry
Background:
- Coronary heart disease (CHD) frequently co-occurs with anxiety and depression, posing treatment challenges due to adverse effects of conventional psychotropic medications.
- Xinkeshu (XKS), a Chinese patent medicine with psycho-cardiac effects, is widely used in China for managing CHD complicated by anxiety or depression.
Approach:
- A systematic review and meta-analysis of 18 randomized controlled trials (RCTs) involving 1907 patients were conducted.
- Searches were performed across nine electronic databases up to February 2022.
- Methodological quality was assessed using the Cochrane risk of bias tool and modified Jadad scale; meta-analysis utilized RevMan 5.3 and Stata 16.0.
Key Points:
- XKS combined with Western medicine (WM) significantly reduced anxiety scores on the Hamilton Anxiety Scale (HAMA) and Zung Self-rating Anxiety Scale (SAS).
- XKS also significantly decreased depression scores on the Hamilton Depression Scale (HAMD) and Zung Self-rating Depression Scale (SDS).
- The combination therapy demonstrated a significantly improved clinical effective rate and reported mild, transient adverse reactions.
Conclusions:
- Current evidence suggests Xinkeshu (XKS) is a potentially effective and safe adjunct therapy for patients with CHD complicated by anxiety or depression.
- The overall quality of included studies was low, highlighting the urgent need for high-quality, large-scale RCTs to confirm these findings.
Ethnopharmacological Relevance:
The incidence of coronary heart disease (CHD) complicated with anxiety or depression is increasing year by year. However, many anti-anxiety drugs or antidepressants have a certain degree of adverse reactions and are not easily accepted by patients. Xinkeshu (XKS), as a proprietary Chinese patent medicine with "psycho-cardiology" effect, is one of the commonly used drugs in the treatment of CHD complicated with anxiety or depression in China.
Aim Of The Study:
To systematically evaluate the efficacy and safety of XKS for CHD complicated with anxiety or depression.
Methods:
Nine different electronic databases were independently searched to include randomized controlled trials (RCTs) of XKS for CHD complicated with anxiety or depression published from inception to February 2022, and the methodological quality was evaluated using the bias risk assessment tool from Cochrane Handbook 5.0 and the modified Jadad scale. Meta-analysis was performed using RevMan 5.3 and Stata 16.0 software. The GRADE Profiler 3.6.1 and TSA 0.9.5.10 beta were adopted to evaluate the certainty and conclusiveness of the evidence.
Results:
A total of 18 RCTs involving 1907 subjects were included. There were 956 subjects in the XKS group and 951 subjects in the control group. Baseline conditions were consistent and comparable between the groups. Compared with single-use western medicine (WM), XKS combined with WM significantly reduced scores of Hamilton Anxiety Scale (HAMA) [Mean difference (MD) = -7.60, 95% confidence interval (95% CI) (-10.37, -4.83), P < 0.000 01], Zung Self-rating Anxiety Scale (SAS) [MD = -10.05, 95% CI (-12.70, -7.41), P < 0.000 01], Hamilton Depression Scale (HAMD) [MD = -6.74, 95% CI (-11.58, -1.90), P = 0.006], and Zung Self-rating Depression Scale (SDS) [MD = -10.75, 95% CI (-17.05,-4.45), P = 0.000 8], as well as improved clinical effective rate [odds ratio (OR) = 4.24, 95% CI (2.47, 7.27), P < 0.000 01]. In terms of safety, 4 studies reported the adverse reactions in detail. The severity was mild and symptoms disappeared after treatment.
Conclusion:
Current evidence indicates that XKS may be effective and safe in the treatment of patients with CHD complicated with anxiety or depression. Since the quality of the literature included in this study was generally low, there is an urgent need for more RCTs with high quality, low bias risk and sufficient sample size to validate our conclusions.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Anxiolytic Drugs: Overview
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
01:18Anxiety: Overview
Individuals with anxiety often experience a range of physical and emotional symptoms, including sweating, trembling, tachycardia, and disturbances in sleep patterns. These symptoms vary in intensity and frequency but are generally disruptive and distressing.
01:26Coronary Artery Disease IV: Preventive Measures
01:30Generalized Anxiety Disorder
01:25Antidepressant Drugs: Overview